ESTRO 2023 - Abstract Book

S4

Saturday 13 May

ESTRO 2023

Purpose: The application of stereotactic body radiotherapy (SBRT) is continuously increasing and is no longer restricted to academic centres thanks to the results of phase II-III clinical trials. The ability to replicate clinical trial outcomes into routine practice depends on the ability to reproduce the technical procedures used in the clinical trial. However, due to large variability in SBRT planning, delivery and reporting between the institutions, interpretation of published SBRT studies can be challenging. This study reports the results of the ESTRO 2021 physics workshop on harmonization and standardization of SBRT planning and delivery. In this work, we evaluated the technical data reported in SBRT clinical trial publications with the aim of: (i) determine if sufficient detail was provided to replicate the treatment and results in routine clinical practice and (ii) provide recommendation on the technical components of patient treatments that should be included when reporting SBRT clinical trial results Methods: A working group (WG) of 12 medical physicists performed a systematic review focusing treatment planning, delivery and reporting parameters in phase II and III SBRT trials (PROSPERO systematic review database #CRD42021286365). The data extraction included information on dose (irradiation technique, patient specific QA, constrains) and IGRT/imaging (margins, motion management, and immobilization). Following data extraction and review, members of the WG voted on whether each collected data field was ‘mandatory’, ‘useful’, or ‘not required’ when reporting a clinical trial. The requirement was based on the required technical information to be able to treat patients at a given centre according to how patients were treated in a given clinical trial. Results: Twenty-two papers were extracted from the initial 2124 reviewed papers. A large variability was found in the reported data, as well as the lack of data for reproducing these treatments in clinical practice. Figure 1 reports the frequency of whether each technical component has been reported in a way that can be reproduced in routine clinical practice. We provided a recommendation on the technical components of patient treatments that should be included when reporting SBRT clinical trial results.

Figure 1: Frequency of whether each technical component has been reported in a way that can be reproduced in routine clinical practice. Conclusions: Our recommendation could help improve the reproducibility of the technical data included in the main SBRT clinical trial document and increase harmonization of SBRT practice.

Teaching Lecture: What's new in deep-learning?

SP-0007 What's new in deep-learning? M. Vakalopoulu France Abstract not available

Teaching Lecture: Patient comfort during radiotherapy

SP-0008 Patient comfort during radiotherapy S. Wong Singapore Abstract not available

Teaching Lecture: The role of brachytherapy in the treatment of primary and recurrent vulvar cancer

SP-0009 The role of brachytherapy in the treatment of primary and recurrent vulvar cancer C. Chargari 1 1 Hôpital Universitaire Pitié Salpetrière, 75013, PARIS, France

Abstract Text Locally advanced vulvar cancer still have a poor prognosis, because of a high risk of local relapse, even in the context of chemoradiation. The morbidity associated with most widely accepted approaches, mainly relying on chemoradiation +/-